Backgraund. The investigation of potential treatment methods for post-COVID syndrome with neurological manifestations within the framework of randomized controlled trials remains one of the priority tasks. Objective: to compare the effects of pharmacotherapy alone versus pharmacotherapy combined with transcranial electrical stimulation on neurological status measures and plasma levels of pro-inflammatory cytokines in patients with post-COVID syndrome. Material and methods. The study included 150 patients with PCS and randomized them into 2 groups (75 patients each): the main group received transcranial electrical stimulation (TES) in addition to monopharmacotherapy, the comparison group received monopharmacotherapy only. The effectiveness of the treatment was analyzed using the MFI-20, MoCa, CGI—S scales and plasma levels of TNF-α, IL-1β, IL-6. Results. The study included 150 patients with post-COVID syndrome presenting neurological symptoms, who were randomized into two groups (75 patients each): the main group received transcranial electrical stimulation in combination with pharmacotherapy, while the comparison group received pharmacotherapy alone. In both groups, Cortexin was used as the pharmacotherapy. The effectiveness of the treatment was evaluated using the MFI-20, MoCA, and CGI—S scales, as well as plasma levels of TNF-α, IL-1β, and IL-6. Conclusion. The results of the study support considering transcranial electrical stimulation as an effective and pathogenetically justified component of complex therapy for post-COVID syndrome with neurological symptoms, accompanied by chronic fatigue and cognitive impairment.
Rubel et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: